weSRCH App on Apple
The economics behind why the healthcare market doesn’t work.
 
Healthcare presents a rare problem in economics for which, a market based system fails to work. One necessary ingredient for an efficient market is that the buyer and seller have equal access to and knowledge of the relevant information. This is fundamentally impossible in health care, because the buyer — the patient — has gone to the seller — the doctor — to discover what is wrong.
 
Thus, the doctor not only has the ability to fix the problem, the doctor also has far more information than the patient. This combined with the fact that the patient has a real problem affecting his or her quality of life means that the only real limiting factor to inflation of healthcare pricing is ability to pay. As a result, we are all very dependent on our doctors having the highest level of ethics in more ways than one.
 
Nevertheless, it means that price inflation is a real threat. America devotes 16% of its GDP to healthcare, versus Europe’s 10% — this is when Europeans are generally healthier than Americans. Moreover, the growth is astounding: back in 1980, Americans spent just over 7%. So the cost is escalating fast. The differences are not due to doctors charging more. Remember, doctors are only part of the healthcare infrastructure and they are generally poorer than they were in the past when less was charged.  
 
The largest sources of the problem with rising healthcare costs comes from other areas: the litigious nature of America, an insurance based infrastructure, the burden being shouldered by corporations, poor organization, and excessive regulation — to name more than a few. In the following parts, I will tackle each of these sources and show how they cause Americans to pay more and get less from their healthcare system.
Next

Why America's Medical System is Failing It: Part II

  2204      Nov 30, -0001
The economics behind why the healthcare market doesn’t work.
 
Healthcare presents a rare problem in economics for which, a market based system fails to work. One necessary ingredient for an efficient market is that the buyer and seller have equal access to and knowledge of the relevant information. This is fundamentally impossible in health care, because the buyer — the patient — has gone to the seller — the doctor — to discover what is wrong.
 
Thus, the doctor not only has the ability to fix the problem, the doctor also has far more information than the patient. This combined with the fact that the patient has a real problem affecting his or her quality of life means that the only real limiting factor to inflation of healthcare pricing is ability to pay. As a result, we are all very dependent on our doctors having the highest level of ethics in more ways than one.
 
Nevertheless, it means that price inflation is a real threat. America devotes 16% of its GDP to healthcare, versus Europe’s 10% — this is when Europeans are generally healthier than Americans. Moreover, the growth is astounding: back in 1980, Americans spent just over 7%. So the cost is escalating fast. The differences are not due to doctors charging more. Remember, doctors are only part of the healthcare infrastructure and they are generally poorer than they were in the past when less was charged.  
 
The largest sources of the problem with rising healthcare costs comes from other areas: the litigious nature of America, an insurance based infrastructure, the burden being shouldered by corporations, poor organization, and excessive regulation — to name more than a few. In the following parts, I will tackle each of these sources and show how they cause Americans to pay more and get less from their healthcare system.
About weVISION: weQuest's are written by G Dan Hutcheson, his career spans more than thirty years, in which he became a well-known as a visionary for helping companies make businesses out of technology. This includes hundreds of successful programs involving product development, positioning, and launch in Semiconductor, Technology, Medicine, Energy, Business, High Tech, Enviorntment, Electronics, healthcare and Business devisions.

You may like this also:

...
17 September, 2019

IMAP Medical Devices

Here describe the IMAP’s experience in healthcare buy-side advisory and deep knowledge of the industry were key factors in successfully closing the transaction.

IMAP
16 September, 2019
PFCD
15 September, 2019
ISMP Canada
13 September, 2019
...
12 September, 2019
Shane A. Snyder
11 September, 2019

Jingfeng Pharmacuetical By Estivita

Jingfeng manages to design products with large market as key products, featured drugs as the main product & supplement with generic drug & its developing strategy.

Estivita
10 September, 2019
David C. Kaslow
09 September, 2019
weSRCH App on Apple

Recent weVISIONs

Open IC Design Platforms ... with Michael Wishart of Efabless
Michael WishartEfabless
20 August, 2019
Tom Caulfield on what's next at GLOBALFOUNDRIES
Tom CaulfieldGLOBALFOUNDRIES
22 July, 2019